Research priorities for non-pharmacological therapies for common musculoskeletal problems: nationally and internationally agreed recommendations.
BACKGROUND
Musculoskeletal problems such as low back pain, neck, knee and shoulder pain are leading causes of disability and activity limitation in adults and are most frequently managed within primary care. There is a clear trend towards large, high quality trials testing the effectiveness of common non-pharmacological interventions for these conditions showing, at best, small to moderate benefits. This paper summarises the main lessons learnt from recent trials of the effectiveness of non-pharmacological therapies for common musculoskeletal conditions in primary care and provides agreed research priorities for future clinical trials.


METHODS
Consensus development using nominal group techniques through national (UK) and international workshops. During a national Clinical Trials Thinktank workshop in April 2007 in the UK, a group of 30 senior researchers experienced in clinical trials for musculoskeletal conditions and 2 patient representatives debated the possible explanations for the findings of recent high quality trials of non-pharmacological interventions. Using the qualitative method of nominal group technique, these experts developed and ranked a set of priorities for future research, guided by the evidence from recent trials of treatments for common musculoskeletal problems. The recommendations from the national workshop were presented and further ranked at an international symposium (hosted in Canada) in June 2007.


RESULTS
22 recommended research priorities were developed, of which 12 reached consensus as priorities for future research from the UK workshop. The 12 recommendations were reduced to 7 agreed priorities at the international symposium. These were: to increase the focus on implementation (research into practice); to develop national musculoskeletal research networks in which large trials can be sited and smaller trials supported; to use more innovative trial designs such as those based on stepped care and subgrouping for targeted treatment models; to routinely incorporate health economic analysis into future trials; to include more patient-centred outcome measures; to develop a core set of outcomes for new trials of interventions for musculoskeletal problems; and to focus on studies that advance methodological approaches for clinical trials in this field.


CONCLUSIONS
A set of research priorities for future trials of non-pharmacological therapies for common musculoskeletal conditions has been developed and agreed through national (UK) and international consensus processes. These priorities provide useful direction for researchers and research funders alike and impetus for improvement in the quality and methodology of clinical trials in this field.
Foster
Nadine E
NE
Dziedzic
Krysia S
KS
van der Windt
Danielle A W M
DA
Fritz
Julie M
JM
Hay
Elaine M
EM
D035843:Biomedical Research / Q000592:standards* / Q000706:statistics & numerical data; D002986:Clinical Trials as Topic / Q000592:standards* / Q000706:statistics & numerical data; D014943:Global Health; D017048:Health Care Costs / Q000706:statistics & numerical data; D006801:Humans; D007391:International Cooperation; D009140:Musculoskeletal Diseases / Q000191:economics / Q000503:physiopathology / Q000628:therapy*; D009141:Musculoskeletal System / Q000503:physiopathology; D017063:Outcome Assessment, Health Care / Q000379:methods / Q000592:standards; D012106:Research / Q000592:standards*; D006113:United Kingdom